Corbus Pharmaceuticals Holdings, Inc.
CRBP
Rank in Stocks
#21227
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in... Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFΓ expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Share Price
$3.41
Last synced: 2026-11-12
Market Cap
$71.06M
Change (1 day)
-14.75%
Change (1 year)
-69.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Category
Healthcare
EPS for Corbus Pharmaceuticals Holdings, Inc. (CRBP)
EPS as of June 2026 TTM: $-6.48
According to Corbus Pharmaceuticals Holdings, Inc.'s latest financial reports, its current EPS (TTM) is $-6.48. At the end of 2025 the company had an EPS of $-5.90, a decrease compared to its 2024 EPS of $-3.68.
EPS history for Corbus Pharmaceuticals Holdings, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-6.48 | 9.83% |
| 2025 | $-5.90 | 60.33% |
| 2024 | $-3.68 | -64.31% |
| 2023 | $-10.31 | 1.58% |
| 2022 | $-10.15 | -8.81% |
| 2021 | $-11.13 | -73.95% |
| 2020 | $-42.72 | 27.33% |
| 2019 | $-33.55 | 14.51% |
| 2018 | $-29.30 | 51.19% |
| 2017 | $-19.38 | 32.92% |
| 2016 | $-14.58 | 72.14% |
| 2015 | $-8.47 | 124.07% |
| 2014 | $-3.78 | 440.00% |
| 2013 | $-0.70 | -81.68% |
| 2012 | $-3.82 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -341.67% |
US
|
|
| $-7.07 | 9.10% |
US
|
|
| $-5.29 | -18.36% |
AU
|
|
| $12.88 | -298.77% |
BE
|
|
| $21.56 | -432.72% |
NL
|
Questions about Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS)
What is Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS)?
Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) over the last twelve months is $-6.48, as of Jun 2026.
What was Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) in 2025?
In 2025, Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) was $-5.90, compared with $-3.68 in 2024.
How has Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) was highest in 2024 ($-3.68) and lowest in 2020 ($-42.72).
How does Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) compare with similar companies?
Corbus Pharmaceuticals Holdings, Inc.'s earnings per share (EPS) ($-6.48) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.